PT2385 CAS No.:1672665-49-4

Introduction

PT2385 is a revolutionary product that has been designed to target solid tumor cancers such as breast, lung, and colorectal cancers. It is a potent inhibitor of the oncogenic transcription factor HIF-2α, which has been identified as a key driver of tumorigenesis in various types of cancer.

The product is manufactured by our company in China, and we have been supplying it to merchants in countries outside China for some time now. In this product introduction, we will highlight the unique features and benefits of PT2385 and how it can help merchants in their cancer research efforts.

Features and Benefits of PT2385

1. Potent HIF-2α Inhibitor

PT2385 is a highly selective and potent HIF-2α inhibitor. HIF-2α is known to be a key driver of tumorigenesis in various types of cancer, and inhibiting it can lead to the reduction of tumor growth and metastasis.

2. High Bioavailability and Safety Profile

PT2385 has been subjected to extensive preclinical and clinical studies. The results demonstrated that it has a high bioavailability and excellent safety profile, making it an ideal drug candidate for cancer treatment.

3. Clinical Trials

PT2385 has undergone multiple clinical trials, which have shown promising results. The Phase 1 clinical trial showed that the drug was well-tolerated, and the preliminary data from the ongoing Phase 2 clinical trial showed encouraging signs of tumor shrinkage and improved patient response rates.

4. Wide Applicability

PT2385 has shown the potential to be effective against various types of solid tumor cancers, including breast, lung, and colorectal cancers. This wide applicability makes it an attractive option for researchers and clinicians looking for new and effective cancer treatments.

Applications of PT2385

1. Cancer Research

PT2385 is an essential tool for cancer researchers looking to understand the mechanisms underlying tumor growth and metastasis. It provides a platform for the development of new and innovative cancer treatments that target HIF-2α and other oncogenic transcription factors.

2. Cancer Treatment

PT2385 has enormous potential as a cancer treatment for solid tumor cancers. The ongoing clinical trials have demonstrated that the drug is well-tolerated and has shown promising results in shrinking tumors and improving patient response rates.

3. Precision Medicine

PT2385 can be used to develop precision medicine approaches for cancer treatment. Its selectivity for HIF-2α makes it an ideal candidate for personalized cancer therapy, as it can be tailored to the patient's specific tumor profile.

Conclusion

PT2385 is a groundbreaking product with enormous potential in cancer research and treatment. Its potency, safety, and wide applicability make it an attractive option for researchers and clinicians looking for new and effective cancer treatments. Our company is proud to manufacture this product and supply it to merchants in countries outside of China. We believe that PT2385 will make a significant contribution to the fight against cancer and will help us move closer to finding a cure.

Chemical Structure : PT2385

CAS No.: 1672665-49-4

 

PT2385(PT-2385)

Catalog No.: URK-V62 Only Used For Lab.

PT2385 (PT-2385) is a potent, selective, and orally active antagonist of HIF2α, binds to HIF2α PAS-B domain (Kd=50 nM) and disrupts HIF2α/ARNT dimer formation.

Biological Activity

PT2385 (PT-2385) is a potent, selective, and orally active antagonist of HIF2α, binds to HIF2α PAS-B domain (Kd=50 nM) and disrupts HIF2α/ARNT dimer formation; allosterically blocks HIF2α dimerization with the HIF1α/2α transcriptional dimerization partner ARNT/HIF1β, disrupts HIF2α, but not HIF1α, heterodimerization with ARNT in Hep3B cells; inhibits the expression of HIF2α-dependent genes, including VEGF-A, PAI-1, and cyclin D1 in ccRCC cell lines and tumor xenografts, also reduces HIF2α mRNA and protein levels in xenograft tumors.
Kidney Cancer
Phase 2 Clinical

Physicochemical Properties

References

1. Wallace EM, et al. Cancer Res. 2016 Sep 15;76(18):5491-500.

2. Chen W, et al. Nature. 2016 Nov 3;539(7627):112-117.

3. Courtney KD, et al. J Clin Oncol. 2018 Mar 20;36(9):867-874.

4. Xie C, et al. Nat Med. 2017 Nov;23(11):1298-1308.

URK-V622_COA

URK-V622_SDS

URK-V622_TDS

 

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, and we do not provide products and services for any personal use!

Why choose us?

• We are committed to sustainable manufacturing practices that reduce waste and lower our environmental impact.
• We use an open management philosophy to encourage colleagues to ask more questions and care more about the company in an open atmosphere.
• Our products have been rigorously tested and proven to be effective in scientific research.
• "Keep improving, pay attention to details, and forge ahead" is our pursuit. A group of product developers who are always responsible and responsible, always put the interests of customers in front. We work hand in hand with customers to develop and innovate together, strive for development, and contribute our infinite strength to the development of the industry!
• Our team of experts is constantly working to improve our products and stay ahead of the latest industry trends.
• The economic benefits of our company are growing, the development of the enterprise is changing day by day, and the work is flourishing.
• We believe that our Nuclear Receptor/Transcription Factor Library products are among the best in the industry.
• The company continues to improve business efficiency and costs, and is committed to creating maximum value for PT2385 CAS No.:1672665-49-4.
• We work closely with our customers to understand their unique needs and provide customized solutions.
• We constantly surpass ourselves, and are committed to continuing to provide manufacturers and customers with leading technology and cost-effective PT2385 CAS No.:1672665-49-4.

Hot Tags: pt2385 cas no.:1672665-49-4, China pt2385 cas no.:1672665-49-4, agonists for endocytosis, inhibitors for pathogen recognition, epigenetic library for epigenetic analysis of epigenetic mechanism research, epigenetic library for epigenetic silencing, inhibitors for drug discovery, inhibitors for immunotherapy